

Special Issue

Exploring Novel Therapies and Drug Efficacy for Inflammatory Bowel Disease

Message from the Guest Editor

Inflammatory Bowel Disease (IBD) is one of the most significant and growing challenges in public health today. Its chronic and debilitating symptoms—including severe abdominal pain, persistent diarrhea, and significant weight loss—profoundly diminish the quality of life for those affected. While conventional treatments have advanced, a large number of patients struggle to achieve or maintain remission, highlighting a critical need for novel therapeutic approaches.

We invite original research, reviews, and short communications on various topics, including but not limited to the following:

- Innovative pharmacological and non-pharmacological interventions.
- The effectiveness of emerging natural compounds, nutraceuticals, and the therapeutic role of antioxidants.
- Preclinical and clinical studies on new drug targets.
- Personalized medicine and biomarkers for predicting treatment response.
- The role of the gut microbiome in therapeutic outcomes.

Our goal is to create a comprehensive and timely collection of research that will advance the field and bring new hope to patients with IBD. We look forward to your valuable contributions.

Guest Editor

Dr. Fabiana Andréa Moura

Faculdade de Nutrição (FANUT), Universidade Federal de Alagoas (UFAL), Maceió 57072-970, Brazil

Deadline for manuscript submissions

30 May 2026



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/253830

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)